Bionano Genomics (BNGO) saw its stock price plummet by 6.10% during intraday trading on Thursday, following the company's announcement of a new stock offering. The genomics company filed to sell 2.03 million shares of common stock, with H.C. Wainwright acting as the exclusive placement agent for the offering.

The sharp decline in Bionano's stock price can be attributed to investor concerns about potential share dilution. When a company issues new shares, it increases the total number of outstanding shares, which can dilute the ownership stake of existing shareholders. This dilution often leads to a decrease in the stock price as the market adjusts to the new share supply.

While the funds raised from this offering could provide Bionano Genomics with additional capital for operations or expansion, the market's immediate reaction suggests that investors are focusing on the short-term impact of share dilution rather than potential long-term benefits. As the details of the offering unfold, investors will be closely watching how the company plans to use the proceeds and whether it can translate this capital infusion into growth that offsets the dilution effect.